SCAMP2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4698765	0.61	1/20
SCHEMBL4699844	0.60	1/20
SCHEMBL2806838	0.58	1/20
SCHEMBL4697700	0.58	1/20
SCHEMBL4699434	0.56	1/20
SCHEMBL4754278	0.56	1/20
SCHEMBL4787917	0.55	1/20
SCHEMBL20558234	0.55	1/20
SCHEMBL4785228	0.54	1/20
SCHEMBL21943341	0.53	1/20
SCHEMBL21942956	0.52	1/20
SCHEMBL4698202	0.51	1/20
SCHEMBL21942979	0.51	1/20
SCHEMBL22024720	0.50	1/20
SCHEMBL22025134	0.50	1/20
SCHEMBL4697939	0.47	1/20
SCHEMBL21943713	0.47	1/20
SCHEMBL3174213	0.46	1/20
SCHEMBL21943016	0.45	1/20
SCHEMBL12000982	0.43	1/20

Clinical trials — most relevant to SCAMP2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle	PHASE2/PHASE3	NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)	PHASE1/PHASE2	RECRUITING
Lovaza's Effect on the Activation of Platelets	PHASE2	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Hong Kong Spinocerebellar Ataxias Registry	nan	RECRUITING
Neuropsychiatry and Cognition in SCA3/MJD	nan	UNKNOWN
Genetic Mechanism of Conserved Ancestral Haplotype in SCA10	nan	UNKNOWN
Genetic Characterization of Parkinson's Disease	nan	COMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Hydroxychloroquin (HCQ) in chILD of Genetic Defect	nan	COMPLETED
Surfactant Derived Protocol in Heart Failure	nan	COMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Genomics of Sudden Cardiac Arrest	nan	ACTIVE_NOT_RECRUITING
Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)	nan	RECRUITING
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy	nan	COMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders	nan	RECRUITING
Evaluation of CEMIP in Pancreatic Cancer	nan	UNKNOWN
Genetic Variation in CLTCL1 and Whole-body Glucose Control	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Biomarkers in Autosomal Dominant Cerebellar Ataxia	nan	COMPLETED
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.	nan	COMPLETED
Open-Label Study of Omega 3 Oil Supplementation for Aging-Related Cognitive Decline	nan	COMPLETED
SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias	nan	COMPLETED
Study of Constitutional Platelet Disease	nan	UNKNOWN
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Genetic Analysis of Hereditary Disorders of Hearing and Balance	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SCAMP2 binder may also engage these)

Protein	Name	Similarity
SCAMP3	Secretory carrier-associated membrane protein 3	0.995	landscape →
Q9ERN0	—	0.993	Q9ERN0 →
O15126	—	0.990	O15126 →
Q58DR5	—	0.989	Q58DR5 →
O35609	—	0.987	O35609 →
P56603	—	0.985	P56603 →
O77735	—	0.984	O77735 →
Q8K021	—	0.982	Q8K021 →
Q28F21	—	0.979	Q28F21 →
Q9SKT3	—	0.979	Q9SKT3 →
Q6GPA8	—	0.973	Q6GPA8 →
Q7F613	—	0.972	Q7F613 →
Q6GM42	—	0.972	Q6GM42 →
Q9M5P2	—	0.972	Q9M5P2 →
Q9SXA5	—	0.971	Q9SXA5 →
Q17QF8	—	0.969	Q17QF8 →
A2YMP7	—	0.969	A2YMP7 →
Q6P0C7	—	0.969	Q6P0C7 →
Q9ZTX0	—	0.968	Q9ZTX0 →
Q8H5X5	—	0.967	Q8H5X5 →
Q9LR68	—	0.967	Q9LR68 →
Q75IC7	—	0.965	Q75IC7 →
Q60EA5	—	0.965	Q60EA5 →
Q8N8F6	—	0.965	Q8N8F6 →
Q9VPB1	—	0.964	Q9VPB1 →
Q9JKE3	—	0.963	Q9JKE3 →
Q9JKD3	—	0.962	Q9JKD3 →
Q9ET20	—	0.962	Q9ET20 →
Q6Z8F5	—	0.962	Q6Z8F5 →
Q3UDR8	—	0.961	Q3UDR8 →